Oculis S.A.

“We’re at an exciting juncture in medicine where the perceived scientific boundaries in treatment across therapeutic areas continue to dissolve.” These words from Jeffrey Jones , chief medical office

Aardvark Therapeutics’ drug candidates are designed to reduce hunger, but the company worked up enough of an appetite among investors to support the company’s initial public offering – the fifth bioph

Oculis has presented positive mid-stage data on the third compound in its pipeline, OCS-05, which demonstrates its potential as the first neuroprotective treatment for a number of optic nerve disorder

Pathalys Pharma, Inc. is nearing the clinical trial finish line with upacicalcet, which it is testing in two Phase III trials for the treatment of secondary hyperparathyroidism (SHPT) in patients wit